Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
Cancer Research UK Clinical Trials Unit, Glasgow, United Kingdom.
Clin Cancer Res. 2017 Dec 15;23(24):7633-7640. doi: 10.1158/1078-0432.CCR-17-1789. Epub 2017 Sep 27.
We sought to identify the genomic abnormalities in squamous cell carcinomas (SCC) arising in ovarian mature cystic teratoma (MCT), a rare gynecological malignancy of poor prognosis. We performed copy number, mutational state, and zygosity analysis of 151 genes in SCC arising in MCT ( = 25) using next-generation sequencing. The presence of high-/intermediate-risk HPV genotypes was assessed by quantitative PCR. Genomic events were correlated with clinical features and outcome. MCT had a low mutation burden with a mean of only one mutation per case. Zygosity analyses of MCT indicated four separate patterns, suggesting that MCT can arise from errors at various stages of oogenesis. A total of 244 abnormalities were identified in 79 genes in MCT-associated SCC, and the overall mutational burden was high (mean 10.2 mutations per megabase). No SCC was positive for HPV. The most frequently altered genes in SCC were (20/25 cases, 80%), (13/25 cases, 52%), and (11/25 cases, 44%). Mutation in was associated with improved overall survival. In 8 of 20 cases with mutations, two or more variants were identified, which were bi-allelic. Ovarian SCC arising in MCT has a high mutational burden, with mutation the most common abnormality. The presence of mutation is a good prognostic factor. SCC arising in MCT share similar mutation profiles to other SCC. Given their rarity, they should be included in basket studies that recruit patients with SCC of other organs. .
我们试图确定在卵巢成熟囊性畸胎瘤(MCT)中发生的鳞状细胞癌(SCC)的基因组异常,这是一种预后不良的罕见妇科恶性肿瘤。我们使用下一代测序对 25 例 MCT 中发生的 SCC 进行了 151 个基因的拷贝数、突变状态和杂合性分析。通过定量 PCR 评估高危/中危 HPV 基因型的存在。将基因组事件与临床特征和结果相关联。MCT 的突变负担较低,平均每个病例只有一个突变。MCT 的杂合性分析表明存在四种不同的模式,这表明 MCT 可能源自卵子发生各个阶段的错误。在 MCT 相关 SCC 中鉴定出 79 个基因中的 244 个异常,整体突变负担很高(平均每兆碱基 10.2 个突变)。没有 SCC 对 HPV 呈阳性。SCC 中最常改变的基因是 (25 例中的 20 例,80%)、 (25 例中的 13 例,52%)和 (25 例中的 11 例,44%)。在 中发生突变与总体生存改善相关。在 20 例 突变中,有 8 例鉴定出两个或更多变体,这些变体都是双等位基因。MCT 中发生的卵巢 SCC 具有很高的突变负担,其中 突变是最常见的异常。 突变的存在是一个良好的预后因素。MCT 中发生的 SCC 与其他 SCC 具有相似的突变谱。鉴于它们的罕见性,它们应被纳入招募其他器官 SCC 患者的篮子研究中。